KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 83 filers reported holding KEROS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,397 | -8.3% | 1,424 | +15.6% | 0.00% | 0.0% |
| Q2 2023 | $49,502 | +11.3% | 1,232 | +18.2% | 0.00% | 0.0% |
| Q1 2023 | $44,493 | -22.2% | 1,042 | -12.5% | 0.00% | -33.3% |
| Q4 2022 | $57,192 | +40.4% | 1,191 | +10.0% | 0.00% | +50.0% |
| Q3 2022 | $40,742 | +36.2% | 1,083 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $29,923 | -49.2% | 1,083 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $58,894 | -75.3% | 1,083 | -73.5% | 0.00% | -33.3% |
| Q4 2021 | $238,838 | +47.9% | 4,082 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $161,484 | -6.9% | 4,082 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $173,363 | -26.1% | 4,082 | +7.1% | 0.00% | -50.0% |
| Q1 2021 | $234,629 | -12.7% | 3,812 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $268,898 | +165.0% | 3,812 | +44.9% | 0.00% | +100.0% |
| Q3 2020 | $101,478 | +2.8% | 2,631 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $98,689 | – | 2,631 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |